{
	"hash": "935df12c03d54f93f540cbef444bb1d9",
	"cards": [
		{
			"slug": "adenosine",
			"title": "Adenosine 6-12-12 Approach",
			"authors": [
				"Bryan Hayes, PharmD"
			],
			"created": "2012/12/06",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"Pharmacology",
				"Critical Care"
			],
			"body": "\n# Adenosine: 6-12-12 adenosine approach\n\nThe ACLS-recommended dosing strategy of 6 mg, 12 mg, and 12 mg for <span class=\"drug\">adenosine</span> may not be appropriate in every situation. There are a few instances when lower or higher dosing should be considered.\n\n_Caveat:_ All recommendations are data-based, but many factors affect successful conversion of paroxysmal supraventricular tachycardia (PSVT) including proper line placement and administration technique.\n\n## Option 1: Starting at higher dose\n\n**Caffeine and theophylline:** Caffeine is an <span class=\"drug\">adenosine</span> blocker and can interfere with the successful reversion of PSVT. In fact, ingestion of caffeine less than 4 hours before a 6-mg <span class=\"drug\">adenosine</span> bolus significantly reduced its effectiveness in the treatment of PSVT. An increased initial <span class=\"drug\">adenosine</span> dose may be indicated for these patients.\n\nRemember that theophylline may require higher dosing as well, because it is similar to caffeine (another methylxanthine), but is not prescribed much in the U.S. anymore.\n\n**_Recommended dosing strategy_** \\[[Cabalag, 2009](http://www.ncbi.nlm.nih.gov/pubmed/20003123)]:\n\n- 1st dose: 12 mg (instead of 6)\n- 2nd/3rd doses: 18 mg (instead of 12)\n\n## Option 2: Starting at lower dose\n\n**Central Line:** The initial <span class=\"drug\">adenosine</span> dose should be reduced if administered through a central line. Remember a central line delivers the <span class=\"drug\">adenosine</span> right where you need it. This recommendation is supported by the 2010 ACLS guidelines. Cases of prolonged bradycardia and severe side effects have been reported after full-dose <span class=\"drug\">adenosine</span> through a central line.\n\n**Carbamazepine or Dipyridamole:** Lower dose for patients on <span class=\"drug\">carbamazepine</span> or <span class=\"drug\">dipyridamole</span> \n\n**Transplanted heart:** Lowr dose for patients with heart transplants\n\n**_Recommended dosing strategy_**\\[[Chang, 2002](http://www.ncbi.nlm.nih.gov/pubmed/11858927); [Neumar, 2010](http://www.ncbi.nlm.nih.gov/pubmed/20956256); [Mc-Intosh-Yellin, 1993](http://www.ncbi.nlm.nih.gov/pubmed/8354807)]:\n\n- 1st dose: 3 mg (instead of 6)\n- 2nd/3rd doses: 6 mg (instead of 12)\n\n**[ALiEM Blog Post](https://www.aliem.com/2012/is-6-12-12-adenosine-approach-always/)**\n\n## References\n\n- McIntosh-Yellin NL, et al. Safety and efficacy of central intravenous bolus administration for termination of supraventricular tachycardia. J Am Coll Cardiol 1993;22:741-5. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8354807)]\n- Cabalag MS, et al. Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia. Acad Emerg Med 2009;17(1):44-9. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20003123)]\n- Chang M, et al. Adenosine dose should be less when administered through a central line. J Emerg Med 2002;22(2):195-8 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11858927)]\n- Neumar RW, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S729-S767. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20956256)]\n"
		},
		{
			"slug": "brugada",
			"title": "Brugada Syndrome",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/05/06",
			"updates": [
				"2017/05/10"
			],
			"categories": [
				"Cardiovascular"
			],
			"body": "\n# Brugada Syndrome\n\n- Genetically linked, cardiac sodium channelopathy\n- High risk for sudden death in young, healthy adults because VTach/VFib \n- Mean age of sudden death = 41 ± 15 years\n- Higher prevalence in males and Asian descent\n- Atrial fibrillation associated in 10-20% cases\n\n## ECG findings\n\n- 3 types\n- Type 1 – Most specific for Brugada Syndrome\n- Highest risk for symptoms of syncope and sudden death\n\n![Examples of type 1, type 2, and type 3 Brugada ECG patterns](https://aliemteam.github.io/aliemcards_cards/images/brugada/image-1.png)\n\n## Differential diagnosis\n\n|                                       |                                       |\n| ------------------------------------- | ------------------------------------- |\n| After electrical cardioversion        | Friedreich ataxia                     |\n| Arrhythmogenic RV dysplasia           | Early repolarization, esp in athletes |\n| Atypical right BBB                    | Hypothermia                           |\n| Acute MI, especiall RV infarct        | Pericardial effusion                  |\n| Acute myopericarditis                 | Pulmonary embolism                    |\n| Compression of RV outflow tract       | Left ventricular hypertrophy          |\n| Disorder of central/auton nerv system | Mediastinal tumor                     |\n| Dissecting aortic aneurysm            | Pectus excavatum                      |\n| Duchenne muscular dystrophy           |                                       |\n\n## Treatment\n\n### Indications for implantable cardiac defibrillator\n\n**Brugada Type 1 PLUS one of following:**\n\n- Aborted sudden cardiac death\n- Syncope, seizure, or noctural agonal respirations without alternative cause\n- Family history of sudden cardiac death (likely from Brugada) AND positive electrophysiology (EPS) study \n- A positive EPS study\n\nOtherwise, close followup with cardiologist.\n\n## References\n\n- Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.Circulation. 2005 Feb 8;111(5):659-70. Epub 2005 Jan 17. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=15655131)]\n"
		},
		{
			"slug": "croup",
			"title": "Croup",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/08/20",
			"updates": null,
			"categories": [
				"Pediatrics",
				"ENT"
			],
			"body": "\n# Croup\n\n- Laryngotracheobronchitis\n- Viral inflammatory condition of the subglottic airway\n- **Typical age:** 6 months-5 years\n- **Cause:** Parainfluenza in 80% cases\n- **Presentation:** hoarse voice, “barky” cough, low-grade fever, stridor, resp distress \n- **Differential diagnosis:** epiglottitis (which does not usually have URI sx and usually more toxic)\n- [Video of child with croup](https://www.youtube.com/watch?v=0lepci-YheI)\n\n## Westley croup scoring system\n\n(Scoring systems not extensively evaluated)\n\n| Finding                             | Points |\n| ----------------------------------- | -----: |\n| **STRIDOR**                         |        |\n| • None                              |      0 |\n| • Only with agitation or excitement |      1 |\n| • At rest with stethoscope          |      2 |\n| • At rest without stethoscope       |      3 |\n| **RETRACTION**                      |        |\n| • None                              |      0 |\n| • Mild                              |      1 |\n| • Moderate                          |      2 |\n| • Severe                            |      3 |\n| **AIR ENTRY**                       |        |\n| • Normal                            |      0 |\n| • Decreased                         |      1 |\n| • Severely decreased                |      2 |\n| **CYANOSIS**                        |        |\n| • None                              |      0 |\n| • With agitation                    |      4 |\n| • At rest                           |      5 |\n| **LEVEL OF CONSCIOUSNESS**          |        |\n| • Normal                            |      0 |\n| • Altered mental status             |      5 |\n\n**Severity:**\n\n- Mild (0-2)\n- Moderate (3-6)\n- Severe (>6)\n\n**Pearl:**\nCheck for cutaneous hemangiomas, because may be subglottic hemangioma (esp in age &lt;6 mo)\n\n**CXR (AP view)**: \n\n- Not helpful to look for “steeple” sign. \n- Poor specificity and sensitivity\n\n## Treatment \n\n1. Keep child calm.\n2. Give supplemental oxygen\n3. <span class=\"drug\">**Racemic epinephrine:**</span> Reduces airway edema. Use for moderate-severe respiratory distress. Observe 3-4 hours for rebound symptoms. Dose: 0.5 mL/kg (onset &lt;30 minutes, duration 2 hours)\n4. <span class=\"drug\">**Dexamethasone:**</span> Reduces severity and duration of croup, even in mild cases ([Bjornson et al., NEJM, 2004](https://www.ncbi.nlm.nih.gov/pubmed/?term=15385657))\n\n- Dose 0.6 mg/kg po\n\n## NO longer part of treatment\n\n1. **Cool mist:** NO added benefit in moderate-severe croup ([Scholnik, JAMA 2006](https://www.ncbi.nlm.nih.gov/pubmed/?term=16537737))\n2. **Humidified air:** NO added benefit ([Moore et al., Cochrane, 2006](https://www.ncbi.nlm.nih.gov/pubmed/?term=16855994))\n\n## References\n\n- Sobol SE, Zapata S. Epiglottitis and Croup. Otolaryn Clin N Am. 2008, 41:551-66 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18435998)]\n- Scolnik D, Coates AL, Stephens D, Da Silva Z, Lavine E, Schuh S.Controlled delivery of high vs low humidity vs mist therapy for croup in emergency departments: a randomized controlled trial. JAMA. 2006 Mar 15;295(11):1274-80. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=16537737)]\n- Moore M, Little P. Humidified air inhalation for treating croup. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002870. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=16855994)]\n- Everard ML. Acute Bronchiolitis and Croup. Pediatr Clin N Am. 2009, 56:1 19-33 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=19135584)]\n- Bjornson CL, Klassen TP, Williamson J, Brant R, Mitton C, Plint A, Bulloch B, Evered L, Johnson DW; Pediatric Emergency Research Canada Network.A randomized trial of a single dose of oral dexamethasone for mild croup.N Engl J Med. 2004 Sep 23;351(13):1306-13. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=15385657)]\n"
		},
		{
			"slug": "dental-infections",
			"title": "Dental Infections",
			"authors": [
				"Hans Rosenberg, MD"
			],
			"created": "2011/04/22",
			"updates": null,
			"categories": [
				"ENT"
			],
			"body": "\n# Dental Infections\n\n- **Dental caries** - demineralization of protective enamel and subsequent tooth decay\n- **Pulpitis** - inflammation of pulp secondary to caries\n- **Periodontitis** - loss of supportive bone structure caused by chronic gingivitis\n\n![Cellulitis, necrotic pulp, and periapical abscess diagram](https://aliemteam.github.io/aliemcards_cards/images/dental-infections/image-1.png)\n\n![Impaction of food and bacteria diagram](https://aliemteam.github.io/aliemcards_cards/images/dental-infections/image-2.png)\n\n## Periapical Abscess\n\nCollection of purulent material at apex of tooth\n\n- Secondary to bacterial invasion from carious destruction of enamel\n- History: Progressive pain, thermal sensitivity\n- Exam: Caries, decayed tooth, pain with percussion, palpation of apex, gingival swelling, erythema, parulis present, mobile tooth\n- Treatment:\n\n- Antibiotics\n\n  - Uncomplicated: <span class=\"drug\">Penicillin</span> or <span class=\"drug\">Clindamycin</span>\n  - Complicated: <span class=\"drug\">Penicillin</span> + <span class=\"drug\">Metronidazole</span>, Piperacillin/Tazobactam, **or** <span class=\"drug\">Clindamycin</span> + <span class=\"drug\">Ceftriaxone</span>\n\n- Pain control\n- I+D if abscess present: probe with 18g needle → purulent → 11 blade stab incision → hemostat blunt dissection +/- packing\n- <span class=\"drug\">Chlorhexidine</span> 0.1% rinses q2-3h if I & D\n- Surgical referral, if complicated infection (Ludwig's, Lemierre's Syndrome)\n\n- Dentist followup:\n\n- Uncomplicated: Generalist in 1-2 days\n- Complicated: Oral Surgery as soon as possible\n\n## Periodontal Abscess\n\n- Localized purulent infection within the gingival wall of the periodontal pocket\n- History: Swelling, pain, loose tooth\n- Exam: Purulent discharge, erythema, fluctuant mass, dental extrusion\n- Treatment:\n\n- Pain Control: Dental block, NSAID’s +/- opioids\n- I & D abscess as needed: 11 blade stab incision → hemostat blunt dissection +/- packing\n- Antibiotics:\n\n  - <span class=\"drug\">Penicillin</span> or <span class=\"drug\">Clindamycin</span>\n  - <span class=\"drug\">Chlorhexidine</span> 0.1% rinses q2-3h\n\n- Dentist followup\n- Generalist in 1-2 days\n\n## Pericoronitis\n\n- Inflammation +/- infection surrounding impacted or partially erupted tooth\n- History: Usually 3rd molar (wisdom tooth), erupting teeth, pain, swelling, halitosis\n- Exam: Erythema, swelling, +/- abscess\n- Treatment: Same as for Periodontal Abscess\n\n  - Pain Control: Dental block, NSAID’s +/- opioids\n  - I & D abscess as needed: 11 blade stab incision → hemostat blunt dissection +/- packing\n  - Antibiotics:\n\n    - <span class=\"drug\">Penicillin</span> or <span class=\"drug\">Clindamycin</span>\n    - <span class=\"drug\">Chlorhexidine</span> 0.1% rinses q2-3h\n\n- Dentist followup: \n- Generalist in 1-2 days\n\n- Definitive treatment: Oral Surgery\n\n## References\n\n- Nguyen DH, Martin JT. Common dental infections in the primary care setting. Am Fam Physician. 2008 Mar 15;77(6):797-802. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18386594)]\n"
		},
		{
			"slug": "emtala-rules",
			"title": "EMTALA Transfer Rules",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/09/14",
			"updates": null,
			"categories": [
				"EMS"
			],
			"body": "\n# EMTALA Transfer Rules\n\nThe Emergency Medical Treatment and Labor Act (EMTALA) is a federal law that requires anyone coming to an ED be stabilized and treated, regardless of their insurance status or ability to pay\n\n- Known as “anti-dumping law”\n- Goal: Ensure “adequate first response to a medical crisis for all patients”\n\n## Rules for the transferring ED\n\nMedically screen patients to determine whether a medical emergency exists (regardless of insurance). This goes beyond a triage assessment.\nStabilize patients with medical emergencies to reasonably ensure that no deterioration will result from patient's transfer.\nRestrict transfer of non-stabilized patients to 2 circumstances:\n\n1. Patient requests a transfer in writing after being informed of the risks involved and the hospital’s duty to treat under EMTALA, or\n2. A physician certifies that the medical benefits expected from transfer outweigh the risks involved in the transfer (e.g. need higher level of care)\n\n**Pregnancy:** When having contractions, an emergency medical condition exists when:\n\n- Inadequate time for safe transfer to another hospital before delivery, or\n- Transfer may pose a threat to the health/safety of patient or unborn child\n\n## Steps when transferring a patient\n\n1. Provide medical treatment to minimize the risk of transfer\n2. Obtain patient’s written consent for transfer\n3. Provide signed certificate of transfer\n4. Assure that the transfer takes place with qualified personnel and equipment\n5. Send copies of medical records related to the emergency condition\n\n## Obligation of receiving ED\n\nIf have available space and qualified personnel for treating the patient:\n\n1. Agree to accept transfer of the patient and to provide appropriate medical tx\n2. Regional referral centers and hospitals with specialized capabilities cannot refuse to accept an appropriate transfer if they have the capacity\n\n## Fines under EMTALA\n\nA physician can be fined for:\n\n- Failing to respond to an emergency while on-call\n- Failing to perform a screening exam\n- Failing to inform emergency patients of the risks and benefits of transfer\n- Signing a transfer certification when he or she can reasonably be expected to know that the risks outweigh the benefits\n\nFine = $25,000 or $50,000 per violation (hospital with &lt;100 beds vs &ge;100 beds)\n\n## References\n\n- EMTALA. Available at: http://www.acep.org/content.aspx?id=25936. Accessed August 1, 2017.\n- AMA Ethics Resource Center. Available at: http://www.ama-assn.org/delivering-care/medical-ethics. Accessed August 1, 2017.\n"
		},
		{
			"slug": "ketofol",
			"title": "Ketofol",
			"authors": [
				"Salim Rezaie, MD"
			],
			"created": "2013/03/20",
			"updates": null,
			"categories": [
				"Pharmacology"
			],
			"body": "\n# Ketamine and Propofol (Ketofol) for Procedural Sedation\n\n## Take Home Points\n\n- <span class=\"drug\">Ketofol</span> is a combination of <span class=\"drug\">ketamine</span> and <span class=\"drug\">propofol</span>.\n- <span class=\"drug\">Ketamine</span> gives you a dissociative sedative, analgesic, and amnestic effect.\n- <span class=\"drug\">Propofol</span> gives you rapid sedation and antiemetic effects. \n- Overall, it appears that <span class=\"drug\">ketofol</span> could have a slightly better time to sedation, and length of sedation, but this is not statistically significant based on available evidence. However, it does appear that <span class=\"drug\">ketofol</span> does have a more steady sedation depth not requiring as many subsequent doses.  \n- More studies needed (it would be great to see a three-armed study comparing <span class=\"drug\">ketofol</span>, <span class=\"drug\">ketamine</span>, and <span class=\"drug\">propofol</span> with appropriate and clinically equivalent dosing for each). \n\n## Ketamine Basics\n\n![Ketamine basics table](https://aliemteam.github.io/aliemcards_cards/images/ketofol/image-1.png)\n\n<span class=\"drug\">Ketamine</span> is a dissociative anesthetic that is a phencyclidine derivative and provides sedation, analgesia, and amnesia. It works by inhibiting catecholamine uptake, which exerts a sympathomimetic effect.\n\n**Typical dose:** 1–2 mg/kg IV or 4–5 mg/kg IM\n\n- Additional doses may be required at increments of 0.5-1 mg/kg. \n\n**Major adverse outcomes:** airway obstruction, hypoxia, apnea, and laryngospasm. \n\n- In a meta-analysis, of 8,282 patients, [Green et al (2009)](http://www.ncbi.nlm.nih.gov/pubmed/19201064) stated that the total incidence of these major adverse outcomes was only 3.9%. \n- Vomiting occurs in about 7–26% of patients.\n\n### What about the elevated intraocular pressure (IOP) and intracranial pressure (ICP) that we are always hearing about?\n\n[Drayna et al (2011)](http://www.ncbi.nlm.nih.gov/pubmed/22169582) found minimal, transient elevations of IOP that were not clinically meaningful. \n\n- The largest difference from baseline IOP occurred at 15 minutes with an estimated change of only 1.09 mmHg.\n\n## Propofol Basics\n\n![Propofol basics table](https://aliemteam.github.io/aliemcards_cards/images/ketofol/image-2.png)\n\n<span class=\"drug\">Propofol</span> is a lipophilic, ultra short-acting hypnotic agent, which works by potentiating GABA receptors on the neuronal lipid membranes. It does not provide any analgesia, and therefore should not be used as a sole agent for sedation. Note that one of its advantages is its anti-emetic property with a very low incidence of vomiting.\n\n**Typical dosing:** 1-2 mg/kg bolus followed by either a continuous infusion at 0.05-0.1 mg/kg/min or by 0.5 mg/kg boluses every 2–3 minutes. \nThe [Pediatric Sedation Research Consortium looked at 49,836 propofol sedation cases](http://www.ncbi.nlm.nih.gov/pubmed/19201064) and found no instances of death associated with propofol. \n\n- CPR was required in 2 cases, aspiration occurred in 4 cases, oxygen desaturation (less than 90% for longer than 30 sec duration) occurred in 716 cases, and central apnea occurred in 143 cases. \n\n## HOW DO YOU MIX KETOFOL?\n\nNo standard dosing regimen established.\n\nMost studies and authors recommend a **1:1 ratio** to provide ease of administration. The medications can be mixed or given sequentially. \n\n**[Click here for full ALiEM blog post](https://www.aliem.com/2013/ketofol-game-changer-procedural-sedation/)**\n\n## References\n\n- Drayna PC, Estrada C, Wang W, Saville BR, Arnold DH. Ketamine sedation is not \nassociated with clinically meaningful elevation of intraocular pressure. _Am J\nEmerg Med_. 2012 Sep;30(7):1215-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22169582)]\n- Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH; Pediatric Sedation\nResearch Consortium.. The incidence and nature of adverse events during pediatric\nsedation/anesthesia with propofol for procedures outside the operating room: a\nreport from the Pediatric Sedation Research Consortium. _Anesth Analg_. 2009\nMar;108(3):795-804.  [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19224786)]\n- Alletag MJ, Auerbach MA, Baum CR. Ketamine, propofol, and ketofol use for\npediatric sedation. _Pediatr Emerg Care_. 2012 Dec;28(12):1391-5; quiz 1396-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23222112)]\n- Shah A, Mosdossy G, McLeod S, Lehnhardt K, Peddle M, Rieder M. A blinded,\nrandomized controlled trial to evaluate ketamine/propofol versus ketamine alone\nfor procedural sedation in children. _Ann Emerg Med_. 2011 May;57(5):425-33.e2. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20947210)]\n- Andolfatto G, Abu-Laban RB, Zed PJ, Staniforth SM, Stackhouse S, Moadebi S,\nWillman E. Ketamine-propofol combination (ketofol) versus propofol alone for\nemergency department procedural sedation and analgesia: a randomized double-blind\ntrial. _Ann Emerg Med_. 2012 Jun;59(6):504-12.e1-2. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22401952)]\n- Green SM, Roback MG, Krauss B, Brown L, McGlone RG, Agrawal D, McKee M, Weiss \nM, Pitetti RD, Hostetler MA, Wathen JE, Treston G, Garcia Pena BM, Gerber AC,\nLosek JD; Emergency Department Ketamine Meta-Analysis Study Group. Predictors of\nairway and respiratory adverse events with ketamine sedation in the emergency\ndepartment: an individual-patient data meta-analysis of 8,282 children. _Ann Emerg\nMed_. 2009 Aug;54(2):158-68.e1-4.[[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19201064)]\n"
		},
		{
			"slug": "paracentesis",
			"title": "Paracentesis for Ascites",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/06/25",
			"updates": null,
			"categories": [
				"Gastroenterology"
			],
			"body": "\n# Spontaneous Bacterial Peritonitis and Paracentesis\n\n_[JAMA Rational Clinical Examination Series 2009](http://www.ncbi.nlm.nih.gov/pubmed/?term=18926597)_\n\n**Bottom line:** It appears safe to perform paracentesis without checking coagulation labs\n\n- 2 prospective studies\n- No instances of significant bleeding despite platelet counts &lt;50K and INR >1.5\n- 2 cases of minor bleeding\n\n**Bottom line:** Albumin likely not needed in therapeutic paracentesis\n\n- 9 prospective randomized studies\n- Pooled 806 paracentesis procedures: No difference with plasma expansion with respect to encephalopathy and death\n\n## Spontaneous Bacterial Peritonitis (SBP) Lab Findings\n\n- Ascites WBC >500 cells/mm3\n- Ascites PMN >250 cells/mm3\n- Ascites pH &lt;7.35\n- Blood-ascites pH gradient >0.1 \n\n## Ascites fluid analysis to assess for SBP (pooled data)\n\n| Lab Finding                 | # patients | (+) LR | (-) LR |\n| --------------------------- | :--------: | :----: | :----: |\n| Ascites WBC >1000 cells/mm3 |     508    |   9.1  |  0.25  |\n| Ascites WBC >500 cells/mm3  |     717    |   5.9  |  0.21  |\n| Ascites PMN >500 cells/mm3  |    1,074   |  10.6  |  0.16  |\n| Ascites PMN >250 cells/mm3  |    1,058   |   6.4  |   0.2  |\n| Ascites pH &lt;7.35         |     129    |   9.0  |  0.31  |\n| Blood-Ascites pH gradient   |     129    |   7.1  |  0.30  |\n\n## Fagan Nomogram\n\n![Fagan nomogram](https://aliemteam.github.io/aliemcards_cards/images/paracentesis/image-1.png)\n\n## References\n\n- Wilkerson RG, Sinert R.Evidence-based emergency medicine/rational clinical examination abstract: The use of paracentesis in the assessment of the patient with ascites. Ann Emerg Med. 2009 Sep;54(3):465-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=18926597)]\n"
		},
		{
			"slug": "radial-head-fracture",
			"title": "Elbow Injuries - Radial Head Fracture",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n# Elbow Injuries: Radial Head Fracture\n\n![Type 1-4 radial head fracture drawing](https://aliemteam.github.io/aliemcards_cards/images/radial-head-fracture/image-1.png)\n\n## X-ray Views\n\n**Elbow XR:** AP, lateral, +/- radiocapitellate view\n\nAssess for indirect signs of fracture or dislocation on lateral elbow view.\n\n- Sail sign or posterior fat pad\n- Radiocapitellate line misalignment\n\n### Mason Classification\n\n| Type | Description                                    |\n| ---- | ---------------------------------------------- |\n| I    | Minimally displaced fracture ≤2 mm             |\n| II   | Fracture fragment displaced >2 mm or angulated |\n| III  | Comminuted and displaced fracture              |\n| IV   | Associated elbow dislocation                   |\n\nMost common elbow fractures in adults\n\n### Operative indications\n\n- \\>3 mm displacement\n- 33% articular surface involvement\n- Angulated >30°\n- Associated elbow dislocation\n\n## Acute Management\n\n- **Type I:** Sling\n- **Type II-IV:** Long-arm posterior splint with elbow at 90° flexion (after type IV elbow dislocation reduced)\n\n## Follow-up Timing\n\n- If operative: ≤3 days\n- If non-operative: &lt;1-2 weeks with early mobilization in 48 hours to minimize elbow stiffness\n\n## References\n\n- Wheeless’ Textbook of Orthopaedics. Available at: http://www.wheelessonline.com/ortho/radial_head_frx. Accessed August 1, 2017.\n- Orthobullets. Available at: http://www.orthobullets.com/trauma/1019/radial-head-fractures. Accessed August 1, 2017.\n- Radiopaedia. Available at: http://radiopaedia.org/articles/radial-head-fractures. Accessed August 1, 2017.\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children’s Hospital, Department of Orthopedics\n"
		},
		{
			"slug": "subarachnoid-hemorrhage",
			"title": "Management of Aneurysmal Subarachnoid Hemorrhage",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/12/17",
			"updates": null,
			"categories": [
				"Neurology"
			],
			"body": "\n# Grading and Management of Aneurysmal Subarachnoid Hemorrhage (SAH)\n\n1. Control rebleeding: 4% incidence in first 24 hrs of bleed\n2. Blood pressure (BP) control:\n\n- No evidence for a target BP\n\n3. “Triple H therapy” to treat vasospasm: Hypervolemia, hypertension, hemodilution\n4. Ventriculostomy, if hydrocephalus (occurs in 33-50% of SAH patients) \n5. <span class=\"drug\">Nimodipine</span>: Vasospasm and delayed cerebral ischemia: Usually occurs 7-10 days after bleed. \n6. Definitive treatment: Microvascular aneurysm clipping or endovascular coil embolization\n\n## Grading Scales\n\n**Hunt-Hess Scale** (subjective and poor inter-rater variability) \n\n|  **Grade**  | **Description**                                                         |\n| :---------: | ----------------------------------------------------------------------- |\n|      0      | Unruptured                                                              |\n|      1      | Asymptomatic, or mild H/A and slight nuchal rigidity                    |\n|      1a     | Acute meningeal/brain reaction, but with fixed neuro deficit            |\n|      2      | Cranial nerve palsy, moderate to severe headache, or nuchal rigidity    |\n|      3      | Mild focal deficit, lethargy, or confusion                              |\n|      4      | Stupor, moderate to severe hemiparesis, or clearly decerebrate rigidity |\n|      5      | Deep coma, decerebrate rigidity, moribund appearance                    |\n\nIncrease by 1 grade for serious system disease, or severe vasospasm on arteriography\n\n**World Federation of Neurosurgical Societies** (WFNS) \n\n|  **WFNS Grade** | **Glasgow Coma Score**  |  **Major Focal Deficit** |\n| :-------------: | :---------------------: | :----------------------: |\n|  0 (unruptured) |          -----          |          ------          |\n|        1        |            15           |          Absent          |\n|        2        |          13-14          |          Absent          |\n|        3        |          13-14          |          Present         |\n|        4        |           7-12          |      Present/absent      |\n|        5        |           3-6           |      Present/absent      |\n\n## References\n\n- Edlow JA, Malek AM, Ogilvy CS. Aneurysmal subarachnoid hemorrhage: update for emergency physicians. J Emerg Med. 2008 Apr;34(3):237-51. Epub 2007 Dec 26. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=18155383)]\n"
		},
		{
			"slug": "tpa-code-dose",
			"title": "TPA Code Dose",
			"authors": [
				"Bryan D. Hayes, PharmD"
			],
			"created": "2013/05/14",
			"updates": null,
			"categories": [
				"Critical Care"
			],
			"body": "\n# TPA: Code Dose of TPA\n\n**Clinical Question:** In the rare situation where fibrinolytics may be indicated in cardiac arrest from PE or Acute Myocardial Infarction (AMI), what’s the dose?\n\n**Take Home Points**\n\n- The dose of <span class=\"drug\">tPA</span> in cardiac arrest is somewhere between **50-100 mg** given as a bolus +/- infusion.\n- According to the [2010 AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care](http://circ.ahajournals.org/content/122/18_suppl_3/S729.full), “Ongoing CPR is not an absolute contraindication for fibrinolysis.”\n- Some studies suggest allowing 15 minutes of CPR for drug to work.\n- Evidence is ‘best’ for PE; data does not support for undifferentiated cardiac arrest.\n- Anticoagulants, such as heparin, were used in most studies along with the fibrinolytic.\n\n![Table describing various study designs](https://aliemteam.github.io/aliemcards_cards/images/tpa-code-dose/image-1.png)\n\n## References\n\n- Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.Circulation. 2010 Nov 2;122(18 Suppl 3):S729-67 [[Source](http://circ.ahajournals.org/content/122/18_suppl_3/S729.full)]\n\nClick here [[Source](https://www.aliem.com/2013/whats-code-dose-of-tpa/)] for full ALiEM blog post\n"
		}
	]
}